We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
STAAR Surgical Company | NASDAQ:STAA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.17 | -0.39% | 43.40 | 43.35 | 43.42 | 45.18 | 43.02 | 44.75 | 195,187 | 18:53:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code:
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
|
Compensatory Arrangements of Certain Officers. |
On December 1, 2023, the Board of Directors of STAAR Surgical Company (the “Company”) elected Lillian Zhou, 41, to serve as a member of the Board of Directors. The Board approved providing Ms. Zhou with the standard director compensation for a director, pro-rated for the remaining portion of the 2023-2024 term.
Ms. Zhou brings more than two decades of capital markets and investment experience to the Company. Most recently, Ms. Zhou was Founder, Chief Investment Officer and Managing Partner of Yulan Capital Management, a Tiger Seed, which operated out of New York and Shanghai from 2013 through June 2023. Prior to Yulan Capital, Ms. Zhou worked at Citadel, Kelusa Capital and Bear Stearns & Co. Ms. Zhou began her career as an investment banking analyst at Credit Suisse in 2004. She is a Chartered Financial Analyst (CFA) and holds a Bachelor of Arts, Economics and Mathematics-Statistics, from Columbia University and an MBA from The Wharton School, University of Pennsylvania.
The appointment of Ms. Zhou to the Board was not the result of any arrangement or understanding between her and any other person or entity. There are no transactions between Ms. Zhou nor any member of her immediate family and the Company or any of its subsidiaries.
On December 1, 2023, Gilbert Kliman, MD, submitted his resignation as a Director of the Company, effective December 1, 2023. Dr. Kliman’s resignation was not submitted as the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Ms. Zhou replaces Dr. Kliman as a member of the Board of Directors.
The information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report, and Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.
Item 7.01 |
Regulation FD Disclosure. |
On December 4, 2023, the Company issued a press release regarding the election of Ms. Zhou to the Board. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
The information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.
Item 9.01 Financial Statements and Exhibits
Exhibit No. |
|
Description |
|
99.1 |
|
||
|
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STAAR Surgical Company |
||
|
||
December 4, 2023 |
By: |
/s/ Tom Frinzi |
|
|
Thomas G. Frinzi |
|
|
President and Chief Executive Officer |
Exhibit 99.1
Lilian Zhou Appointed to STAAR Surgical Board of Directors
LAKE FOREST, CA, December 4, 2023 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023.
“We welcome Lilian Zhou as a new member to our Board of Directors. Lilian is an accomplished investment portfolio manager who worked at highly regarded Wall Street investment institutions before founding her own firm a decade ago,” said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical’s Board of Directors. "We look forward to Lilian’s contributions as a former institutional shareholder of STAAR with an in-depth and global perspective of healthcare, ophthalmology and STAAR’s opportunity."
Lilian Zhou brings more than two decades of capital markets and investment experience to STAAR. Most recently, Ms. Zhou was Founder, Chief Investment Officer and Managing Partner of Yulan Capital Management, a Tiger Seed, which operated out of New York and Shanghai from 2013 through June 2023. Prior to Yulan Capital, Ms. Zhou worked at Citadel, Kelusa Capital and Bear Stearns & Co. Lilian began her career as an investment banking analyst at Credit Suisse in 2004. Ms. Zhou is a Chartered Financial Analyst (CFA) and holds a Bachelor of Arts, Economics and Mathematics-Statistics, from Columbia University and an MBA from The Wharton School, University of Pennsylvania.
STAAR also reported today that Gil Kliman, M.D., has decided to leave the board, effective December 1, in order to more fully devote his time and energies to his other commitments. Tom Frinzi, STAAR’s Chair of the Board stated, “STAAR has benefitted greatly from Dr. Kliman’s extensive ophthalmology, commercial and medical device experience and we sincerely thank Gil for his dedicated service. He has been a steadfast supporter of STAAR, and we hope to continue to benefit from his insights in the future.”
Other current members of STAAR’s Board of Directors include Stephen Farrell, Tom Frinzi, Aimee Weisner, Elizabeth Yeu, M.D., and K. Peony Yu, M.D.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL product line. More than 2,500,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.
CONTACT: Investors & Media
Brian Moore
Vice President, Investor Relations and Corporate Development
(626) 303-7902, Ext. 3023
bmoore@staar.com
Document And Entity Information |
Dec. 01, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Dec. 01, 2023 |
Entity Registrant Name | STAAR Surgical Co |
Entity Central Index Key | 0000718937 |
Entity Emerging Growth Company | false |
Entity File Number | 0-11634 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 95-3797439 |
Entity Address, Address Line One | 25651 Atlantic Ocean Drive |
Entity Address, City or Town | Lake Forest |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92630 |
City Area Code | 626 |
Local Phone Number | 303-7902 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of each class | Common |
Trading Symbol(s) | STAA |
Name of each exchange on which registered | NASDAQ |
1 Year STAAR Surgical Chart |
1 Month STAAR Surgical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions